BALTIMORE, May 15 /PRNewswire/ -- Lentigen Corporation announced today
that it has received four National Institutes of Health (NIH) small
business innovation research (SBIR) grants to collaborate with leading
scientists. Through these grants, Lentigen will apply its proprietary
lentiviral vector (LV) technology to the development of novel
immunotherapeutic treatments for diseases of high unmet medical need:
-- Melanoma, with Michael Nishimura, Ph.D, Associate Professor of Surgery,
Medical University of South Carolina
-- Hepatitis C virus (HCV) infection, also with Dr. Nishimura
-- Epstein-Barr virus (EBV)-related diseases, with Adrian Wiestner,
M.D./Ph.D., Principal Investigator, National Cancer Institute
-- Chronic lymphocytic leukemia (CLL), also with Dr. Wiestner
Together with its collaborators, Lentigen will develop lentiviral vectors designed to target specific cells related to each of these diseases. For melanoma, HCV, and EBV, the vectors will transduce T cells, which play a central role in cell-mediated immunity, with proteins known as T cell receptors (TCRs) that have been engineered to attack the targeted disease. For CLL, the vectors will carry weakened cells of this cancer combined with other substances designed to trigger an immune response.
"These innovation research grants are enabling us to extend the application of our lentiviral vector technology to a wider range of diseases while working with distinguished researchers to address the urgent need for novel biotherapeutics and vaccines in areas of high unmet medical need," said Tim Ravenscroft, Lentigen's CEO.
About Lentigen Corporation
Lentigen Corporation is a privately owned biotechnology company focused
on the development of lentiviral vector technology for a wide range of
therapeutic, vaccine and research applications in biotechnology and
medicine. Lentiviral vectors are the most efficient vehicles for the
|SOURCE Lentigen Corporation|
Copyright©2008 PR Newswire.
All rights reserved